<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018339</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 402-010</org_study_id>
    <nct_id>NCT04018339</nct_id>
  </id_info>
  <brief_title>A Study of RTA 402 in Obese Adults</brief_title>
  <official_title>Phase I Study of RTA 402 in Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate changes in body weight and body composition in obese adults after repeated
      oral administration of RTA 402 once daily for 16 weeks, using placebo as a control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">May 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in weight measured by Bioelectrical Impedance Analysis</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in fat mass measured by Dual Energy X-ray Absorption</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in lean body mass measured by Dual Energy X-ray Absorption</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in skeletal muscle mass index measured by Dual Energy X-ray Absorption</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in waist</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in grip</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in visceral adipose tissue measured by Magnetic Resonance Imaging</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in abdominal subcutaneous adipose tissue measured by Magnetic Resonance Imaging</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in muscle mass measured by Magnetic Resonance Imaging</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in body fat mass measured by Bioelectrical Impedance Analysis</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in segmental muscle mass measured by Bioelectrical Impedance Analysis</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in total body water measured by Bioelectrical Impedance Analysis</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in extracellular water measured by Bioelectrical Impedance Analysis</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in basal metabolic rate measured by Bioelectrical Impedance Analysis</measure>
    <time_frame>Through study completion, approximately 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Obese Adult Male</condition>
  <arm_group>
    <arm_group_label>RTA 402 5mg or 10mg oral administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone methyl</intervention_name>
    <description>Bardoxolone methyl 5 mg capsules</description>
    <arm_group_label>RTA 402 5mg or 10mg oral administration</arm_group_label>
    <other_name>RTA 402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing an inert placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written voluntary informed consent to participate in the study

          -  Male aged ≥ 20 and &lt; 50 years at the time of consent

          -  BMI ≥ 25.0 kg/m2 measured at screening

          -  Waist circumference (umbilical position) ≥ 85 cm measured at screening.

          -  MRI-measured visceral fat area ≥ 100 cm2 measured at screening

        Exclusion Criteria:

          -  Subjects who have undergone weight control procedures (weight loss medicine, surgical
             therapy, exercise therapy, bariatric diet, etc.) at a medical institution within 3
             months before the screening

          -  Subjects with conditions requiring treatment other than obesity

          -  History of cardiac failure (e.g., a prior diagnosis of congestive cardiac failure
             defined as NYHA class III or IV or a history of hospitalization for cardiac failure)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Applied Bio-Pharmatech Kurume Clinical Pharmacology Clinic</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bardoxolone Methyl</keyword>
  <keyword>Obese adult</keyword>
  <keyword>body weight</keyword>
  <keyword>body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

